[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Rhea-AI Filing Summary

United Therapeutics (UTHR) Chairperson & CEO reported option exercises and share sales in mid-November 2025. On 11/18/2025 and 11/19/2025, the executive exercised a total of 8,000 stock options at an exercise price of $120.26 per share and sold 8,000 shares of common stock at weighted average prices around $470–$475 per share. After these transactions, the executive held 130 shares directly and additional shares indirectly through a spouse and multiple family trusts. The filing states that these trades were made under a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025, covering a tranche of 294,000 stock options that expire on March 15, 2026 and running until the earlier of exhaustion of that tranche or December 31, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	11/18/2025		S(1)		1,500	D	$470.5333(2)	2,630	D
Common Stock	11/18/2025		S(1)		1,000	D	$472.595	1,630	D
Common Stock	11/18/2025		S(1)		1,500	D	$475.095	130	D
Common Stock	11/19/2025		M(1)		4,000	A	$120.26	4,130	D
Common Stock	11/19/2025		S(1)		2,000	D	$474.2178(3)	2,130	D
Common Stock	11/19/2025		S(1)		2,000	D	$474.95(4)	130	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(5)
Common Stock								258,117	I	by Trust(6)
Common Stock								45,596	I	by Spouse(7)
Common Stock								15,962	I	by Trust(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$120.26	11/18/2025		M(1)			4,000	03/15/2020	03/15/2026	Common Stock	4,000	$0.00	86,000	D
Stock Option	$120.26	11/19/2025		M(1)			4,000	03/15/2020	03/15/2026	Common Stock	4,000	$0.00	82,000	D

Explanation of Responses:

1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $469.96 to $470.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $473.82 to $474.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $474.825 to $475.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

6. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

7. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

8. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UTHR's CEO report on this Form 4?

The Chairperson & CEO of United Therapeutics (UTHR) reported exercising 8,000 stock options and selling 8,000 shares of common stock on 11/18/2025 and 11/19/2025.

At what prices were the UTHR stock options exercised and shares sold?

The stock options were exercised at $120.26 per share. The reported weighted average sale prices for the common stock ranged from about $470.53 to $475.10 per share across multiple trades.

Is the UTHR CEO trading under a Rule 10b5-1 plan?

Yes. The filing states that the option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025.

How many UTHR shares does the CEO hold after these transactions?

Following the reported transactions, the CEO holds 130 shares directly and additional shares indirectly through a spouse and several family trusts with reported indirect positions such as 324,518 and 258,117 shares in two trusts.

How many UTHR stock options remain from the CEO's affected grant?

After the reported exercises, the CEO beneficially owns 82,000 stock options at an exercise price of $120.26 that are scheduled to expire on March 15, 2026.

What are the key terms of the CEO's 10b5-1 trading plan for UTHR shares?

The plan covers a tranche of 294,000 stock options expiring on March 15, 2026 and will continue until the earlier of the tranche’s exhaustion or December 31, 2025.